The US Food and Drug Administration (FDA) has approved two chemically similar NA inhibitors (zanamivir and oseltamivir—wwPDB CCD IDs ZMR and G39, respectively) that prevent the spread of infection with efficacy against a broad range of NA subtypes (Note: Oseltamivir is an oral pro‐drug, which is converted during passage through the liver into its active metabolite oseltamivir carboxylate). The gene discussed is XK; the disease is infection.